Diquafosol-tetrasodium-INS365-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDiquafosol tetrasodiumCat. No.: HY-B0606CAS No.: 211427-08-6Synonyms: INS365分式: CHNNaOP分量: 878.23作靶點(diǎn): P2Y Receptor作通路: GPCR/G Protein儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) H2O : 32 mg/mL

2、(36.44 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.1387 mL 5.6933 mL 11.3865 mL5 mM 0.2277 mL 1.1387 mL 2.2773 mL10 mM 0.1139 mL 0.5693 mL 1.1387 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Diquafosol tetrasodium種P2Y2受體激動(dòng)劑，

3、可刺激眼睛表 的液體和粘蛋分泌，于眼病的局部治療。體外研究Cell viability significantly decreased after treatment with 30% diluted diquafosol for 1 hour and 6 hours aftertreatment with 10% and 20% diluted diquafosol. Twenty-four hours after wounding monolayers, 3%1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEdiquafosol, and 0

4、.3% HCECs exhibits significantly more wound healing than the control 1.體內(nèi)研究 In a rat dry eye model, the P2Y2 agonist diquafosol tetrasodium is found to improve surface health, based onincreases in tear fluid secretion, corneal epithelial resistance, and release of glycoprotein-containing moietiesfro

5、m goblet cells. Beginning at 2 weeks and continuing for an additional 2 weeks, maximal declines in dyepenetrance of approximately 50% occurred with doses of diquafosol tetrasodium as low as 1% 2. INS365significantly suppresses corneal damage at concentrations of more than 0.1% w/v 3.PROTOCOLCell Ass

6、ay 1 The viabilities of human corneal epithelial cells (HCECs) are determined using a MTT assay. Cells aresubconfluent Diquafosol (100 mL diluted 10%, 20%, or 30%) or DMEM (100 mL) is added to controls. After 1,6, and 24 h, plates are washed three times with PBS to remove the drugs. Cell viabilities

7、 are evaluated afterincubating for 24 h. MTT is then added to each well. Samples are incubated in the dark for 4 h at 37oC, andmedia are then removed. Precipitates are resuspended in DMSO. Absorbances are measured on a platereader at 570 nm 1.MCE has not independently confirmed the accuracy of these

8、 methods. They are for reference only.Animal Rats: An SD rat dry eye model is used in which exorbital lacrimal gland extirpation decreased the SchirmerAdministration 2 test score by at least 50%. After 8 weeks, when significant increases occurred in corneal epithelialpermeability, INS365-containing

9、eye drops are applied six times daily for the next 4 weeks at concentrationsfrom 0.03% to 3.0%. Corneal barrier function is evaluated based on measurements with a modified anteriorfluorometer of fluorescein penetrance at 1, 2, and 4 weeks after initial application. After INS365 application,the perio

10、dic acidSchiff reagent (PAS)stained area is evaluated in histologic sections of the tarsal andbulbar conjunctiva 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Lee JH, et al. Comparison of cytotoxicities and wound healing effects of diqu

11、afosol tetrasodium and hyaluronic acid on human cornealepithelial cells. Korean J Physiol Pharmacol. 2017 Mar;21(2):189-195.2. Fujihara T, et al. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol VisSci. 2001 Jan;42(1):96-100.3. Fujihara T, et al. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dryeye model. J Ocul Pharmacol Ther. 2002 Aug;18(4):363-70.McePdfHeightCaution: Product